Repurposing of Tamoxifen Against the Oral Bacteria
- PMID: 33634670
- PMCID: PMC7957305
- DOI: 10.4274/tjps.galenos.2019.23500
Repurposing of Tamoxifen Against the Oral Bacteria
Abstract
Objectives: Tamoxifen (TAM), which is used for treating breast cancer, has exhibited another important function as an antimicrobial agent. The objective of this study is to investigate the antibacterial action of TAM against the bacteria present in the human oral cavity.
Materials and methods: The bacteria present in the human oral cavity were isolated from healthy individuals. Different concentrations of TAM were tested against the isolated bacteria. Additionally, bactericidal and bacteriostatic effects of TAM were also determined.
Results: Out of 23 isolated bacteria, a greater number of Gram-positive bacteria were highly susceptible to the low concentrations of TAM than Gram-negative bacteria. Kytococcus sedentarius, which is Gram-positive bacterium, and Pseudomonas stutzeri, which is Gram-negative bacterium, needed a high minimum inhibitory concentration value of TAM (2.5 mg/mL) to be inhibited by TAM's bacteriostatic action. Resistance to TAM was also observed in three strains of Gram-positive and four strains of Gram-negative bacteria.
Conclusion: TAM has shown a potential antibacterial effect against the bacteria present in the oral cavity, especially against Gram-positive bacteria. This effect is mostly bacteriostatic. This study also found bacterial resistance toward TAM.
Keywords: Bacteria; Gram-negative; Gram-positive; oral cavity; tamoxifen.
Similar articles
-
Molecular and pharmacokinetic evaluation of rat hepatic and gastrointestinal cytochrome p450 induction by tamoxifen.Pharmacology. 2001;63(4):210-9. doi: 10.1159/000056136. Pharmacology. 2001. PMID: 11729359
-
Regulation of Lipid Membrane Partitioning of Tamoxifen by Ionic Strength and Cholesterol.Pharm Res. 2020 Feb 10;37(3):53. doi: 10.1007/s11095-020-2771-8. Pharm Res. 2020. PMID: 32043169
-
Tamoxifen sensitivity-testing of glioblastomas: comparison of in vitro and in vivo results.Acta Neurochir (Wien). 2001;143(6):563-73. doi: 10.1007/s007010170061. Acta Neurochir (Wien). 2001. PMID: 11534673
-
Pomegranate sensitizes Tamoxifen action in ER-α positive breast cancer cells.J Cell Commun Signal. 2011 Dec;5(4):317-24. doi: 10.1007/s12079-011-0138-y. Epub 2011 Jun 27. J Cell Commun Signal. 2011. PMID: 21706446 Free PMC article.
-
Tamoxifen Resistance: Emerging Molecular Targets.Int J Mol Sci. 2016 Aug 19;17(8):1357. doi: 10.3390/ijms17081357. Int J Mol Sci. 2016. PMID: 27548161 Free PMC article. Review.
Cited by
-
Efficacy of Tamoxifen Metabolites in Combination with Colistin and Tigecycline in Experimental Murine Models of Escherichia coli and Acinetobacter baumannii.Antibiotics (Basel). 2024 Apr 24;13(5):386. doi: 10.3390/antibiotics13050386. Antibiotics (Basel). 2024. PMID: 38786115 Free PMC article.
-
Tooth loss in breast cancer patients: A comparison between tamoxifen-treated and non-treated patients.Med Oral Patol Oral Cir Bucal. 2024 Jul 1;29(4):e552-e558. doi: 10.4317/medoral.26528. Med Oral Patol Oral Cir Bucal. 2024. PMID: 38794935 Free PMC article.
-
Drug Repurposing Approaches towards Defeating Multidrug-Resistant Gram-Negative Pathogens: Novel Polymyxin/Non-Antibiotic Combinations.Pathogens. 2022 Nov 25;11(12):1420. doi: 10.3390/pathogens11121420. Pathogens. 2022. PMID: 36558754 Free PMC article. Review.
-
Exploring Darunavir, Rilpivirine and Etravirine as Potential Therapies for Bladder Cancer: Efficacy and Synergistic Effects.Biomedicines. 2024 Mar 14;12(3):647. doi: 10.3390/biomedicines12030647. Biomedicines. 2024. PMID: 38540260 Free PMC article.
References
-
- Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339:1609–1618. - PubMed
-
- Shahbaz K. Tamoxifen: Pharmacokinetics and pharacodynamics. J Pharm Res. 2017;1:1–8.
-
- Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov. 2003;2:205–213. - PubMed
-
- Bogush TA, Polezhaev BB, Mamuchey IA, Bogush EA, Polotsky BE, Tjulandin SA, Ryabov AB. Tamoxifen never ceases to amaze: New findings on non-estrogen receptor molecular targets and mediated effects. Cancer Invest. 2018;36:211–220. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources